129 related articles for article (PubMed ID: 33046972)
1. Genetic variants in the Folic acid Metabolic Pathway Genes predict outcomes of metastatic Colorectal Cancer patients receiving first-line Chemotherapy.
Jiang L; Li S; Yuan M; Ma L; Lin Y; Zhu W; Du H; Wang M; Chen T; Zhu L
J Cancer; 2020; 11(22):6507-6515. PubMed ID: 33046972
[No Abstract] [Full Text] [Related]
2. Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer.
Zhang K; Meng Y; Cao X; Xu Y; Du M; Wu Y; Liu L
Cancer Med; 2019 Jul; 8(7):3428-3436. PubMed ID: 31090204
[TBL] [Abstract][Full Text] [Related]
3. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in autophagy-related gene
Yu T; Ben S; Ma L; Jiang L; Chen S; Lin Y; Chen T; Li S; Zhu L
Front Oncol; 2022; 12():876424. PubMed ID: 35992821
[TBL] [Abstract][Full Text] [Related]
5. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
Matsusaka S; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio A; Ueno M; Yang D; Ning Y; Parekh A; Okazaki S; Berger MD; Ichikawa W; Mizunuma N; Lenz HJ
Mol Cancer Ther; 2016 Jun; 15(6):1405-11. PubMed ID: 26983880
[TBL] [Abstract][Full Text] [Related]
6. GADD45B as a Prognostic and Predictive Biomarker in Stage II Colorectal Cancer.
Zhao Z; Gao Y; Guan X; Liu Z; Jiang Z; Liu X; Lin H; Yang M; Li C; Yang R; Zou S; Wang X
Genes (Basel); 2018 Jul; 9(7):. PubMed ID: 30029519
[No Abstract] [Full Text] [Related]
7. Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients.
Abdallah EA; Fanelli MF; Buim ME; Machado Netto MC; Gasparini Junior JL; Souza E Silva V; Dettino AL; Mingues NB; Romero JV; Ocea LM; Rocha BM; Alves VS; Araújo DV; Chinen LT
Int J Cancer; 2015 Sep; 137(6):1397-405. PubMed ID: 25721610
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer.
Li S; Xu K; Gu D; He L; Xie L; Chen Z; Fan Z; Zhu L; Du M; Chu H; Zhang Z; Wu Y; Ni M; Wang M
J Gastroenterol; 2019 Nov; 54(11):939-949. PubMed ID: 30923916
[TBL] [Abstract][Full Text] [Related]
9. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
10. Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer.
Wang H; Peng R; Chen X; Jia R; Huang C; Huang Y; Xia L; Guo G
Oncol Lett; 2018 Apr; 15(4):5553-5560. PubMed ID: 29552193
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
[TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
15. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
Abad A; Martínez-Balibrea E; Viéitez JM; Alonso-Orduña V; García Alfonso P; Manzano JL; Massutí B; Benavides M; Carrato A; Zanui M; Gallego J; Grávalos C; Conde V; Provencio M; Valladares-Ayerbes M; Salazar R; Sastre J; Montagut C; Rivera F; Aranda E
Ann Oncol; 2018 Feb; 29(2):439-444. PubMed ID: 29145602
[TBL] [Abstract][Full Text] [Related]
16. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract][Full Text] [Related]
17. Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy.
Jiang H; Li B; Wang F; Ma C; Hao T
Oncol Lett; 2019 Aug; 18(2):1157-1162. PubMed ID: 31423175
[TBL] [Abstract][Full Text] [Related]
18. Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
Zawiah M; Yousef AM; Kadi T; Yousef M; Majdalawi K; Al-Yacoub S; Al-Hiary R; Tantawi D; Mukred R; Ajaj AR
Drug Metab Pers Ther; 2018 Dec; 33(4):201-205. PubMed ID: 30207288
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study.
Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
Acta Oncol; 2018 Nov; 57(11):1445-1454. PubMed ID: 30375911
[TBL] [Abstract][Full Text] [Related]
20. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
